La jolla pharmaceutical company (LJPC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue
Net product sales

7,591

7,250

5,706

5,703

4,395

4,184

3,470

1,593

809

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

85

44

253

234

410

647

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

7,591

7,250

5,706

5,703

4,395

4,184

3,470

1,593

809

0

0

0

0

85

44

253

234

410

647

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Cost of product sales

716

787

554

551

500

1,200

256

129

58

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

9,183

20,860

21,182

22,043

21,244

27,567

30,439

30,867

28,429

26,909

19,093

20,808

17,765

20,177

16,992

12,404

12,715

9,455

7,781

6,686

5,170

3,726

2,625

1,597

1,996

2,059

948

700

655

509

474

336

34

-

-

177

-

4

9

Selling, general and administrative

8,152

10,709

10,782

11,323

12,320

18,843

21,139

22,164

23,016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

-

-

-

-

-

-

-

-

-

-

7,390

6,022

5,503

-

4,349

3,466

4,053

2,813

3,353

3,972

3,796

3,137

2,436

2,689

3,134

4,343

3,225

2,463

3,548

2,898

2,974

2,877

637

469

423

727

478

698

901

Total operating expenses

18,051

32,356

32,518

33,917

34,064

47,610

51,834

53,160

51,503

38,846

26,483

26,830

23,268

25,009

21,341

15,870

16,768

12,268

11,134

10,658

8,966

6,863

5,061

4,286

5,130

6,402

4,173

3,163

4,203

3,407

3,448

3,213

671

469

423

904

478

702

910

Loss from operations

-10,460

-25,106

-26,812

-28,214

-29,669

-43,426

-48,364

-51,567

-50,694

-38,846

-26,483

-26,830

-23,268

-24,924

-21,297

-15,617

-16,534

-11,858

-10,487

-10,658

-8,966

-6,863

-5,061

-4,286

-5,130

-6,402

-4,173

-3,163

-4,203

-3,407

-3,448

-3,213

-671

-469

-423

-904

-478

-702

-910

Interest expense

2,406

2,376

2,863

2,806

2,729

2,723

2,926

1,654

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

190

310

501

604

713

731

545

443

166

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income—related party

4,100

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

1,869

-127

-2,362

-2,202

-2,016

-1,992

-2,381

-1,211

166

-

195

101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of derivative liabilities upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,015

Adjustments to fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,227

-4,485

5,954

-12,854

3,993

5,382

-6,029

480

2,985

Financing transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

28

37

46

51

53

25

13

8

11

14

9

2

2

3

1

1

1

3

-1

1

1

0

0

236

-2

-

-

Net loss

-8,591

-25,233

-29,174

-30,416

-31,685

-45,418

-50,745

-52,778

-50,528

-38,546

-26,288

-26,729

-23,240

-

-21,251

-15,566

-

-

-

-

-

-

-

-

-

-6,399

-4,172

-3,162

-4,202

-3,102

-2,222

-7,697

5,284

-13,323

3,570

4,714

-6,509

-222

-3,104

Convertible preferred stock dividends earned

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-191

337

562

93

313

205

76

186

-

3

-78

-

247

87

Net loss attributable to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,208

-4,509

-3,724

-4,295

-3,415

-2,427

-7,773

5,098

-13,517

3,567

4,792

-6,509

-469

-3,191

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,481

-

-10,474

-10,650

-8,955

-

-5,052

-4,284

-5,128

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted (usd per share)

-0.32

-0.93

-1.08

-1.12

-1.17

-1.68

-1.93

-2.02

-2.22

-1.75

-1.19

-1.21

-1.26

-1.45

-1.23

-0.90

-0.96

-0.69

-0.70

-0.70

-0.59

-0.17

-0.37

-0.53

-0.93

12.32

-5.45

-6.77

-12.26

-

-0.18

-0.67

-

-

-

-

-

-

-

Weighted-average common shares outstanding - basic and diluted (in shares)

27,238

27,170

27,135

27,108

27,035

26,538

26,226

26,182

22,742

22,202

22,125

22,123

18,410

17,280

17,211

17,211

17,210

17,212

14,899

15,251

15,242

15,365

13,646

8,122

5,535

4,433

827

550

350

-

13,253

11,603

-

-

-

-

-

-

-

Net (loss) income per share basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2.44

-

6.69

0.39

-6.87

-0.49

-4.13

Net (loss) income per share diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

0.28

0.01

-6.87

-0.49

-4.13

Shares used in computing basic net (loss) income per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,092

-

533

12,389

947

947

772

Shares used in computing diluted net (loss) income per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,472,245

-

12,880

556,871

947

947

772